Dose Finding Study of Zanzalintinib With Pembrolizumab and Cetuximab in Head and Neck SCC (NCT06912087)
A Phase I Study of Zanzalintinib With Pembrolizumab and Cetuximab in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck
🩺 Plain-English Summary (8th-Grade Level)
This Phase I clinical trial evaluates the safety, tolerability, and optimal dosing of Zanzalintinib in combination with Pembrolizumab and Cetuximab in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M HNSCC). The study aims to establish the maximally tolerated dose (MTD) and recommended Phase II dose (RP2D) while also exploring efficacy outcomes, including progression-free survival (PFS) and overall survival (OS).
Who can join: Review the eligibility criteria below.
Location: University of Chicago Medicine Comprehensive Cancer Center — Chicago, Illinois
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- University of Chicago Medicine Comprehensive Cancer Center — Chicago, Illinois
📞 Contact the Study Coordinator
Phone: (855) 702-8222
Email: cancerclinicaltrials@bsd.uchicago.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Head and Neck Neoplasms
- Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689) — La Jolla, California
- Access to Care Pilot for ED-Presenting Head and Neck Cancer Patients (ENRICH-HNC) — Orlando, Florida
- Molecular and Genomic Profiling of Head and Neck Tumors — The Bronx, New York
- EMST in Patients Undergoing CRT for HNCA — Milwaukee, Wisconsin
- Head and Neck Cancer Study Project in the Geriatric Population — Providence, Rhode Island
Explore by condition: All Head and Neck Neoplasms clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.